It not only uncovers a novel PDE1A/YTHDF2/STAT3 signaling pathway in NSCLC progression but also provides novel therapeutic strategies to treat NSCLC patients with metastasis. This evidence concerns the gene YTHDF2 and non-small cell lung carcinoma.